Aberrant methylation of the @entity17946 promoter in primary small cell, nonsmall cell lung and XXXX .

@entity1 @entity0 @entity5 @entity1149 @entity2 @entity7090 @entity151 @entity17946
DNA methylation alteration of several genes contributes to @entity1 tumorigenesis. @entity17946 , a member of the D-type cyclins, is implicated in cell cycle regulation and malignant transformation. In our study, we examined the methylation status of the @entity17946 promoter in @entity151 ( @entity151 ), @entity1149 ( @entity1149 ), @entity0 and @entity5 cell lines. We observed that aberrant methylation of @entity17946 was present in 32 of 56 (57%) @entity151 cell lines, 7 of 32 (22%) @entity151 tissues; 25 of 61 (47%) @entity1149 cell lines, 19 of 48 (40%) @entity1149 tissues; 18 of 30 (60%) @entity0 cell lines and 19 of 63 (30%) @entity0 tissues. Methylation was more frequent in the @entity5 cell lines compared to the primary breast and @entity151 (p = 0.007 and p = 0.001, respectively). Methylation was rare in the control tissue samples; 0 of 12 peripheral blood lymphocytes; 0 of 12 buccal epithelial cells; 0 of 18 nonmalignant lung tissues and 3 of 28 (11%) nonmalignant breast tissues. Promoter methylation correlated with loss of transcript by reverse transcription PCR (RT-PCR) in 9 of 11 (6 lung, 5 breast) @entity5 cell lines tested. Two cell lines that were not methylated also lacked expression, suggesting that other mechanisms of inactivation may be involved. Expression was restored by treatment with the demethylating agent, 5 aza 2' @entity7090 , in all 9 methylated cell lines. Our results confirm earlier reports in @entity0 and indicate that aberrant methylation of @entity17946 may contribute to the pathogenesis of the 2 major @entity2 .
